Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 29, 2022 20:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

First novel, nonstimulant option for adults with ADHD in 20 yearsADHD affects an estimated 10 million adults in the U.S. ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,...
April 13, 2022 16:11 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

Annual Report on Form 10-K filed on April 13, 2022Reiterates full year 2022 financial guidance provided on February 28, 2022 and reiterated on April 4, 2022 ROCKVILLE, Md., April 13, 2022 (GLOBE...
April 04, 2022 17:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

Annual Report on Form 10-K for fiscal year ended December 31, 2021 to be filed in the near termReiterates full year 2022 financial guidance provided on February 28, 2022 ROCKVILLE, Md., April 04,...
March 17, 2022 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
March 02, 2022 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Participate in Annual Cowen Health Care Conference

ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 28, 2022 16:05 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early...
February 22, 2022 16:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
February 22, 2022 08:00 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
December 08, 2021 08:30 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
November 24, 2021 18:58 ET | Source: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Targeted in Ransomware Incident

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations No ransom payments have been made by the Company ROCKVILLE, Md., Nov. 24,...